Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Katsura, Y.
Right arrow Articles by Matsuoka, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Katsura, Y.
Right arrow Articles by Matsuoka, T.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes Care, Vol 21, Issue 10 1759-1763, Copyright © 1998 by American Diabetes Association

ARTICLES

Hepatocyte growth factor in vitreous fluid of patients with proliferative diabetic retinopathy and other retinal disorders

Y Katsura, T Okano, M Noritake, H Kosano, H Nishigori, S Kado and T Matsuoka
Fifth Department of Internal Medicine, Tokyo Medical College, Ibaraki, Japan. y-katsu@tokyo-med.ac.jp

OBJECTIVE: To determine whether hepatocyte growth factor (HGF) is elevated in the vitreous fluid of patients with proliferative diabetic retinopathy (PDR). RESEARCH DESIGN AND METHODS: Vitreous fluid samples were obtained at the time of vitreoretinal surgery from 73 eyes of PDR patients and from 17 eyes of nondiabetic patients (control subjects) who had macular hole, rhegmatogenous retinal detachment, or epiretinal membrane (9, 4, and 4 eyes, respectively) but no associated proliferative vitreoretinopathy Stages of PDR were classified as active or quiescent. Concentrations of HGF and vascular endothelial growth factor (VEGF) in vitreous fluid were determined by enzyme-linked immunosorbent assay (ELISA). RESULTS: Intravitreous concentrations of HGF (median [range]) were significantly higher in diabetic patients with PDR (6.00 ng/ml [0.75-22.21) than in control patients (2.86 ng/ml [0.75-5.801). Intravitreous concentrations of VEGF were also higher in diabetic patients with PDR (1.62 ng/ml [0.15-7.91) than in control patients (0.16 ng/ml [0.160.29]). Both VEGF and HGF concentrations were significantly higher in patients with active retinopathy than in those with quiescent retinopathy However, vitreous concentrations of HGF were unrelated to those of VEGE CONCLUSIONS: We found that levels of HGF in vitreous fluid of PDR patients are significantly higher than in nondiabetic patients and that the levels of HGF are elevated in the active PDR stage. This suggests that HGF stimulates or perpetuates neovascularization in PDR.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Annals of Clinical & Laboratory ScienceHome page
J.-H. Lee, W. Lee, O. H. Kwon, J.-H. Kim, O. W. Kwon, K. H. Kim, and J.-B. Lim
Cytokine Profile of Peripheral Blood in Type 2 Diabetes Mellitus Patients with Diabetic Retinopathy
Ann. Clin. Lab. Sci., January 1, 2008; 38(4): 361 - 367.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
E. S. Colombo, G. Menicucci, P. G. McGuire, and A. Das
Hepatocyte Growth Factor/Scatter Factor Promotes Retinal Angiogenesis through Increased Urokinase Expression
Invest. Ophthalmol. Vis. Sci., April 1, 2007; 48(4): 1793 - 1800.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
A. C. Clermont, M. Cahill, H. Salti, S. L. Rook, C. Rask-Madsen, L. Goddard, J. S. Wong, D. Bursell, S. E. Bursell, and L. P. Aiello
Hepatocyte Growth Factor Induces Retinal Vascular Permeability via MAP-Kinase and PI-3 Kinase without Altering Retinal Hemodynamics.
Invest. Ophthalmol. Vis. Sci., June 1, 2006; 47(6): 2701 - 2708.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
H Funatsu, H Yamashita, H Noma, T Mimura, K Sakata, and S Hori
Risk evaluation of outcome of vitreous surgery for proliferative diabetic retinopathy based on vitreous level of vascular endothelial growth factor and angiotensin II
Br. J. Ophthalmol., August 1, 2004; 88(8): 1064 - 1068.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
D. R. Hinton, C. Spee, S. He, S. Weitz, W. Usinger, L. LaBree, N. Oliver, and J. I. Lim
Accumulation of NH2-Terminal Fragment of Connective Tissue Growth Factor in the Vitreous of Patients With Proliferative Diabetic Retinopathy
Diabetes Care, March 1, 2004; 27(3): 758 - 764.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
R. Simo, A. Lecube, J. Garcia-Arumi, E. Carrasco, and C. Hernandez
Hepatocyte Growth Factor in the Vitreous Fluid of Patients With Proliferative Diabetic Retinopathy: Its relationship with vascular endothelial growth factor and retinopathy activity
Diabetes Care, January 1, 2004; 27(1): 287 - 288.
[Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
K. Yamane, A. Minamoto, H. Yamashita, H. Takamura, Y. Miyamoto-Myoken, K. Yoshizato, T. Nabetani, A. Tsugita, and H. K. Mishima
Proteome Analysis of Human Vitreous Proteins
Mol. Cell. Proteomics, November 1, 2003; 2(11): 1177 - 1187.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
R Nicoletti, I Venza, G Ceci, M Visalli, D Teti, and A Reibaldi
Vitreous polyamines spermidine, putrescine, and spermine in human proliferative disorders of the retina
Br. J. Ophthalmol., August 1, 2003; 87(8): 1038 - 1042.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
H. Funatsu, H. Yamashita, H. Noma, H. Mochizuki, T. Mimura, T. Ikeda, and S. Hori
Outcome of Vitreous Surgery and the Balance between Vascular Endothelial Growth Factor and Endostatin
Invest. Ophthalmol. Vis. Sci., March 1, 2003; 44(3): 1042 - 1047.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
Y. Mitamura, A. Tashimo, Y. Nakamura, H. Tagawa, K. Ohtsuka, Y. Mizue, and J. Nishihira
Vitreous Levels of Placenta Growth Factor and Vascular Endothelial Growth Factor in Patients With Proliferative Diabetic Retinopathy
Diabetes Care, December 1, 2002; 25(12): 2352 - 2352.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
Y. Mitamura, S. Takeuchi, K. Ohtsuka, A. Matsuda, N. Hiraiwa, and M. Kusakabe
Tenascin-C Levels in the Vitreous of Patients With Proliferative Diabetic Retinopathy
Diabetes Care, October 1, 2002; 25(10): 1899 - 1899.
[Full Text]

Home page
 Arch OphthalmolHome page
H. Noma, H. Funatsu, H. Yamashita, S. Kitano, H. K. Mishima, and S. Hori
Regulation of Angiogenesis in Diabetic Retinopathy: Possible Balance Between Vascular Endothelial Growth Factor and Endostatin
Arch Ophthalmol, August 1, 2002; 120(8): 1075 - 1080.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
H Funatsu, H Yamashita, Y Nakanishi, and S Hori
Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy
Br. J. Ophthalmol., March 1, 2002; 86(3): 311 - 315.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
L. E. Benjamin
Glucose, VEGF-A, and Diabetic Complications
Am. J. Pathol., April 1, 2001; 158(4): 1181 - 1184.
[Full Text] [PDF]

Home page
 IOVSHome page
M. C. Briggs, I. Grierson, P. Hiscott, and J. A. Hunt
Active Scatter Factor (HGF/SF) in Proliferative Vitreoretinal Disease
Invest. Ophthalmol. Vis. Sci., September 1, 2000; 41(10): 3085 - 3094.
[Abstract] [Full Text]

Home page
 Vasc MedHome page
M. Meier and G. L King
Protein kinase C activation and its pharmacological inhibition in vascular disease
Vascular Medicine, August 1, 2000; 5(3): 173 - 185.
[Abstract] [PDF]

Home page
 Br. J. Ophthalmol.Home page
A. Cantón, R. Burgos, C. Hernández, C. Mateo, R. M Segura, J. Mesa, and R. Simó
Hepatocyte growth factor in vitreous and serum from patients with proliferative diabetic retinopathy
Br. J. Ophthalmol., July 1, 2000; 84(7): 732 - 735.
[Abstract] [Full Text]

Home page
 IOVSHome page
W. Cai, S. L. Rook, Z. Y. Jiang, N. Takahara, and L. P. Aiello
Mechanisms of Hepatocyte Growth Factor-Induced Retinal Endothelial Cell Migration and Growth
Invest. Ophthalmol. Vis. Sci., June 1, 2000; 41(7): 1885 - 1893.
[Abstract] [Full Text]

Home page
 Br. J. Ophthalmol.Home page
M. BOULTON
A role for hepatocyte growth factor in diabetic retinopathy?
Br. J. Ophthalmol., July 1, 1999; 83(7): 763 - 764.
[Full Text]

Home page
 Br. J. Ophthalmol.Home page
K. Shinoda, S. Ishida, S. Kawashima, T. Wakabayashi, T. Matsuzaki, M. Takayama, K. Shinmura, and M. Yamada
Comparison of the levels of hepatocyte growth factor and vascular endothelial growth factor in aqueous fluid and serum with grades of retinopathy in patients with diabetes mellitus
Br. J. Ophthalmol., July 1, 1999; 83(7): 834 - 837.
[Abstract] [Full Text]

Home page
 Proc. Natl. Acad. Sci. USAHome page
V. Stellmach, S. E. Crawford, W. Zhou, and N. Bouck
Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor
PNAS, February 27, 2001; 98(5): 2593 - 2597.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1998 by the American Diabetes Association.